Innate Pharma (IPHA) Q3 2026 earnings review
Innate has cash until 2028, but AstraZeneca delays key results
Innate Pharma, a French developer of cancer drugs, now has cash, but its most important trial result comes later. Money from Sobi, which licensed Innate's skin-lymphoma drug, and a share sale lifted cash to €97 million. But AstraZeneca, which runs the lung cancer trial of Innate's drug monalizumab, now expects results in the first half of 2027. By our math, the money lasts about nine months past that point.
| Revenue excluding a one-off Sanofi item, first nine months | €0.9M €2.3M a year earlier |
|---|---|
| Cash and investments | €96.8M €21.4M at the end of June |
| Cash used in the quarter, by our math | about €18M loan repayments included |
| Cash outlook | Unchanged lasts until the end of March 2028 |
⚖️ Verdict: 🔴 Bearish
The story got worse, because Innate must now fund half a year more of waiting before its biggest test. The good news: Sobi paid as promised, and Innate kept every date for its skin-lymphoma drug.
The question now is whether Innate reaches those results and the filing for its skin-lymphoma drug without selling more shares. If spending eases, the cash lasts as planned; if trial costs climb, Innate may need its $75 million share-sale programme sooner. Cash at the end of December and the first patient dosed early next year will tell.
🐂 Bull Case
Sobi Paid for Lacutamab's Final Trial
Lacutamab is Innate's antibody against cutaneous T-cell lymphoma, a rare blood cancer that appears in the skin. Sobi, a Swedish drug company, licensed it in a deal that closed in September. With that money, Innate opened TELLOMAK-3, the final-stage (Phase 3) trial that must confirm the benefit.
- Upfront from Sobi: $75 million
- Further payments tied to Sézary syndrome, the form that reaches the blood: up to $40 million
This matters because lacutamab no longer draws on Innate's own cash. A new slide also dates "a potential US accelerated approval in Sézary syndrome in H1 2028", a faster route based on earlier data.
What to watch: the first patient dosed in TELLOMAK-3, planned for the first quarter of 2027. A start on time keeps the late-2027 filing realistic.
Innate's Nectin-4 Drug Shows Responses Beyond Bladder Cancer
IPH4502 is the cancer drug Innate owns outright. It is an antibody-drug conjugate (ADC), an antibody that carries a toxic payload to tumour cells carrying the protein Nectin-4.
Enrolment in the trial's dose-finding stage closed in July with 76 patients. New investor slides list responses in lung and head-and-neck cancers as well as bladder cancer, with "limited hematological toxicity", meaning little damage to blood cells.
This matters because Padcev, the existing Nectin-4 drug, carries approval only for bladder cancer. But the slides give no response rates, and Eli Lilly and MSD run rival drugs, so the edge rests on design until data appear.
What to watch: response rates in the November 18 poster. Clear responses in lung cancer would support Innate's case for use beyond bladder tumours.
🐻 Bear Case
AstraZeneca Delayed the Lung Cancer Trial Results
Monalizumab is an antibody meant to stop tumours from switching off the immune cells that attack them. AstraZeneca is testing it with its own drug durvalumab in PACIFIC-9, a late-stage trial in lung cancer that surgery cannot remove. Innate can still earn up to $825 million from the deal.
On October 27, AstraZeneca moved the expected results to the first half of 2027. In its September half-year report, Innate still pointed to data by the end of 2026. The company blamed the trial's event-driven design: such a study reads out only after a set number of patients' cancers progress.
This matters because PACIFIC-9 decides most of what monalizumab is worth to Innate. Success could trigger milestone payments, but Innate has not said how much falls due on a positive result. Failure would end that stream, while Innate still owes its share of the trial's costs, about €40 million on its June balance sheet.
What to watch: AstraZeneca's first headline result, now due by the end of June 2027. A positive result would make the size of Innate's milestone payment the next figure to demand.
Cash Lasts to 2028 Only If Spending Eases
Chief executive Jonathan Dickinson pointed to a "strengthened cash position". Cash and investments did reach €96.8 million in September, thanks to Sobi's licensing payment and a share sale.
By our math, the drug developer used about €18 million in the quarter, loan repayments included. At that pace, the money runs out around mid-February 2028, about six weeks before Innate's own date.
Spending will likely rise, not fall, because Innate runs the Phase 3 of lacutamab, its skin-lymphoma antibody, from early 2027. It also holds $75 million of unused capacity to sell new US shares.
What to watch: cash at the end of December, in the full-year results. Another quarter near €18 million would leave the March 2028 date relying on money Innate has not raised.
Finance Chief Frédéric Lombard Leaves at Year-End
Frédéric Lombard, Innate's finance chief, will step down on December 31 "to pursue new career opportunities", the company said. Innate has started "a search of potential candidates" and has named no successor.
The exit adds to a run of leadership changes. Markus Jensen replaced Sonia Quaratino as medical chief on September 1. Before that, a restructuring cut full-time staff from 174 to 120 in the year to June.
This matters because the finance chief runs the cash plan, the bank loans and any share sale, and 2027 will test all three at once.
What to watch: whether Innate names a new finance chief before December 31. A vacancy into 2027 would leave no permanent finance chief in charge during the costliest year.
Risks this quarter didn't answer
Several standing risks got no new numbers, because the release gave dates and cash but no trial data, share count or contract detail.
- Rival drugs aimed at Nectin-4, a tumour protein: Innate's slides list Eli Lilly, MSD and Hengrui; response rates in the November 18 poster allow the first fair comparison.
- Detail on IPH4502, Innate's own Nectin-4 drug: Innate has shown no response rate or chosen dose; the poster will show whether that changes.
- Dates for lacutamab, the skin-lymphoma antibody: Innate held them this quarter after earlier slips; first patient dosing in early 2027 is the test.
- Pace of the lacutamab Phase 3: the filing needs the trial under way; the enrolment rate during 2027 will show whether that holds.
- Bank loans and a partner dispute: Innate keeps repaying the loans; the year-end accounts will update a contested contract claim.
💲 Other KPIs
Revenue rose from €2.3 million a year earlier, but only because Innate booked €2.5 million that Sanofi had paid for an option it let lapse. Excluding that item, sales fell about 61% by our math. Only about €0.3 million came in the third quarter, so Sobi's upfront has not reached revenue yet.
Debt fell by about €4 million in the quarter, from €20.2 million in June, as Innate kept repaying its state-backed and building loans. A year ago it stood at €24.8 million. By our math, debt now equals about 17% of cash and investments, against about 95% in June.
🔮 Guidance
Unchanged. Innate still expects its cash to last until the end of March 2028. That date rests on June cash, the Sobi upfront and the August share sale. By our math, the lung cancer delay cuts the time between that result and the end of the cash to about nine months, from 15.
Delayed. AstraZeneca now expects the first headline results from PACIFIC-9, its lung cancer trial of Innate's monalizumab, in the first half of 2027. The previous date was the second half of 2026. AstraZeneca, not Innate, runs the trial, which finished enrolling in September 2025.
Unchanged. Innate will show the first dose-finding results for IPH4502, its Nectin-4 cancer drug, at ENA, a European cancer research meeting in Barcelona. An investor event in London follows the same day. Innate first targeted the first half of 2026 for these data, so this date already reflects one delay.
Unchanged. Innate plans to dose the first patient in TELLOMAK-3, the final-stage trial of its skin-lymphoma antibody, between January and March 2027. The start has moved before: Innate once aimed for the first half of 2026, then the second half. Over the past year, the time left to the start shrank by only three months.
Unchanged. Innate still plans to file in the second half of 2027 for accelerated approval in Sézary syndrome, the lymphoma's blood-borne form. Accelerated approval is a faster US route based on early data. The filing rests on Phase 2 results but needs the final-stage trial under way first.
New. Innate's slides now place a possible US accelerated approval in Sézary syndrome in the first half of 2028. That period overlaps the end of the cash horizon in March 2028. So any Sobi payment tied to approval would likely arrive near or after the point where today's cash runs out.
❓ Key Questions
How will Innate book Sobi's $75 million upfront?
Revenue so far this year shows almost none of it. Because Innate runs the final lacutamab trial, accounting may spread the payment over years, and the answer shapes reported revenue through 2028.
What triggers Sobi's $40 million of near-term payments?
Innate ties them to Sézary syndrome, the blood-borne form of the lymphoma. Payment on the filing in late 2027 would land inside the cash horizon; payment on approval might not.
How much would AstraZeneca pay if PACIFIC-9 succeeds?
Innate has not split the remaining milestones by event. With results now due in the first half of 2027, investors need to know what a positive result is worth in cash, and when it would arrive.
Does the March 2028 cash date include full trial costs?
By our math, the third quarter's pace would use the cash by mid-February 2028. A split of spending between lacutamab, IPH4502 and early research would show how much room the plan has.
How many shares does Innate have after the August sale?
The release gave no share count. The August sale added about 17.6 million shares, nearly a fifth more, and the unused US share-sale programme could add more.